Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Overcoming Resistance Mechanisms to Melanoma Immunotherapy

American Journal of Clinical Dermatology(2024)10.1007/s40257-024-00907-7Source: DataRank Database

Overcoming Resistance Mechanisms to Melanoma Immunotherapy is a research paper published in American Journal of Clinical Dermatology (2024). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.41)OA: greenTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

David J. Bozym,Giuseppe Tarantino ORCID,Ryan J. Sullivan ORCID,David Liu ORCID,Russell W. Jenkins ORCID

Live enrichment

PubMed:39636504 PMC:PMC12594210 OpenAlex:https://openalex.org/W4405079275

National Institute on Aging

Grant: R38AG070229

National Institutes of Health

Grant: 1R38AG070229-01A1

MGH Diseases of Aging Pathway Via Stimulating Access to Research in Residency (MGH DAP StARR)

FWCI

3.41

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12594210/pdf/nihms-2121280.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40257-024-00907-7.pdf

publisherhttps://link.springer.com/article/10.1007/s40257-024-00907-7/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12594210

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research03 medical and health sciences0302 clinical medicine

MeSH Terms

Immune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansImmunotherapyMelanomaSkin NeoplasmsBiomarkers, TumorTreatment OutcomeDrug Resistance, NeoplasmNeoadjuvant TherapyCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Keywords

ImmunotherapyMedicineMelanomaBlockadeClinical trialIpilimumabImmunologyMonoclonal antibodyImmune checkpointImmune systemOncologyCancer researchAntibodyInternal medicineSkin NeoplasmsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansImmune Checkpoint InhibitorsArticleNeoadjuvant Therapy

Overcoming Resistance Mechanisms to Melanoma Immunotherapy

FAIR Checklist

Authors (6)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)